<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18172" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bacillus Calmette Guerin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Okafor</surname>
            <given-names>Chika N.</given-names>
          </name>
          <aff>Capefear Valley Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rewane</surname>
            <given-names>Ayesan</given-names>
          </name>
          <aff>Rush University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Momodu</surname>
            <given-names>Ifeanyi I.</given-names>
          </name>
          <aff>Campbell University School of OM</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chika Okafor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayesan Rewane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ifeanyi Momodu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18172.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Bacillus Calmette-Guerin (BCG) is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. The vaccine was developed by Calmette and Guerin and was first administered to human beings in 1921. BCG is the only vaccine against tuberculosis. It is the most widely administered vaccine and usually a part of the routine newborn immunization schedule. BCG vaccine also offers protection against non-tuberculous mycobacterial infections like leprosy and Buruli ulcer. This activity reviews the mode of action of the BCG vaccine and highlights the role of the interprofessional team in educating patients about tuberculosis prevention.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mode of action of the BCG vaccine.</p></list-item><list-item><p>Review the indications for the BCG vaccine.</p></list-item><list-item><p>Summarize the clinical relevance of the BCG vaccine.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes in patients receiving the BCG vaccine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18172&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18172">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18172.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bacillus Calmette-Gu&#x000e9;rin (BCG) is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. The vaccine was developed by Calmette and Gu&#x000e9;rin and was first administered to human beings in 1921. BCG is the only vaccine against tuberculosis. It is the most widely administered vaccine and usually a part of the routine newborn immunization schedule.&#x000a0; BCG vaccine also offers protection against non-tuberculous mycobacterial infections&#x000a0;like&#x000a0;leprosy and Buruli ulcer. It is also used in the treatment of superficial carcinoma of the bladder.</p>
        <p>BCG vaccine&#x000a0;is a fairly safe vaccine and&#x000a0;it is not associated with severe complications. Prior to the mycobacterial infection, vaccine-induced or acquired naturally can protect against subsequent&#x000a0;infection due to&#x000a0;mycobacteria including tuberculosis.<xref ref-type="bibr" rid="article-18172.r1">[1]</xref>&#x000a0; Prior infection with nontuberculous mycobacteria and <italic toggle="yes">Mycobacterium tuberculosis</italic> can confer natural protection against tuberculosis infection.<xref ref-type="bibr" rid="article-18172.r2">[2]</xref><xref ref-type="bibr" rid="article-18172.r3">[3]</xref>&#x000a0;Protection against tuberculosis infection is usually due to the immune response to mycobacterial antigens. Prior contained latent infection with <italic toggle="yes">Mycobacterium tuberculosis</italic> can provide up to&#x000a0;80 percent protection against disease with subsequent exposure.<xref ref-type="bibr" rid="article-18172.r4">[4]</xref>&#x000a0;In patients with previous active disease, there is an increased risk of recurrence of active tuberculosis due to distinct strains in both HIV-uninfected and HIV-infected patients.<xref ref-type="bibr" rid="article-18172.r5">[5]</xref><xref ref-type="bibr" rid="article-18172.r6">[6]</xref><xref ref-type="bibr" rid="article-18172.r7">[7]</xref><xref ref-type="bibr" rid="article-18172.r8">[8]</xref><xref ref-type="bibr" rid="article-18172.r9">[9]</xref><xref ref-type="bibr" rid="article-18172.r10">[10]</xref>&#x000a0;Bacille Calmette-Gu&#x000e9;rin (BCG) has been associated with a reduction in childhood mortality which is&#x000a0;not attributable to tuberculosis.&#x000a0; Reduction in childhood mortality may be due to epigenetic reprogramming of the nucleotide-binding oligomerization domain (NOD2) receptor.<xref ref-type="bibr" rid="article-18172.r11">[11]</xref><xref ref-type="bibr" rid="article-18172.r12">[12]</xref><xref ref-type="bibr" rid="article-18172.r13">[13]</xref><xref ref-type="bibr" rid="article-18172.r14">[14]</xref> &#x000a0;</p>
        <p>BCG vaccine can be&#x000a0;given either intracutaneously or intradermally. Research is currently being conducted on respiratory administration since natural infection, and sensitization to<italic toggle="yes"> Mycobacterium tuberculosis</italic> in humans tend to occur in the respiratory system.<xref ref-type="bibr" rid="article-18172.r15">[15]</xref><xref ref-type="bibr" rid="article-18172.r16">[16]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-18172.s3" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>Groups to consider for BCG vaccination include</bold>
</p>
        <p>
<bold>Children: Newborns and infants have the greatest benefit from BCG vaccination </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Infants and children &#x02264;five years with a high risk of exposure to active pulmonary TB.</p>
          </list-item>
          <list-item>
            <p>Healthy neonates <xref ref-type="bibr" rid="article-18172.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>School-age children (aged 7 to 14) not previously vaccinated.<xref ref-type="bibr" rid="article-18172.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Developed Countries: Consider BCG vaccination in infants and children &#x02264;5 years in the following conditions </bold>
<xref ref-type="bibr" rid="article-18172.r19">[19]</xref>
<xref ref-type="bibr" rid="article-18172.r20">[20]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prolonged exposure to a patient with untreated, inadequately treated, or isoniazid and rifampin-resistant M. tuberculosis if separation from such exposure is not possible.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Exposure to MDR-TB</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Consider vaccination in travelers, health care workers, and individuals in the community with exposure to multidrug-resistant (MDR-) tuberculosis.</p>
          </list-item>
          <list-item>
            <p>Administer to unvaccinated, tuberculin-negative individuals.</p>
          </list-item>
        </list>
        <p>
<bold>Health Care Workers</bold>
</p>
        <p>Routine vaccination of health care workers is not recommended in the United States since infection with tuberculosis is low. BCG vaccine also interferes with the result of a tuberculin skin test that is used to detect Mycobacterium tuberculosis infection. In health care workers, the efficacy of BCG vaccination is not definite.<xref ref-type="bibr" rid="article-18172.r21">[21]</xref>&#x000a0;Strict adherence to&#x000a0;tuberculosis infection control practices should be emphasized in areas with a high incidence of&#x000a0;disease transmission.</p>
        <list list-type="bullet">
          <list-item>
            <p>Consider BCG vaccination in healthcare workers in regions with high TB transmission&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Consider vaccination in health care workers from low-risk countries taking care of patients or refugees in TB-endemic countries</p>
          </list-item>
        </list>
        <p>BCG immunization guidelines depend on the prevalence of tuberculosis infection.<xref ref-type="bibr" rid="article-18172.r22">[22]</xref><xref ref-type="bibr" rid="article-18172.r23">[23]</xref>&#x000a0;Childhood BCG immunization should be routine in countries with a high prevalence of tuberculosis.&#x000a0; In countries with low to intermediate rates of TB (&#x0003c;5/100,000 smear-positive cases per year), BCG immunization should be administered to children at particular risk of TB exposure <xref ref-type="bibr" rid="article-18172.r23">[23]</xref> ( ie children exposed to multidrug-resistant disease).</p>
        <p>BCG vaccination policy is determined by the regional prevalence of tuberculosis infection.&#x000a0; Routine neonatal vaccination is recommended by the WHO in countries with moderate to severe prevalence of tuberculosis.&#x000a0; Close contacts of patients with TB infection and healthcare workers exposed to patients'&#x000a0;multidrug-resistant tuberculosis infections with negative tuberculin tests should receive BCG vaccination.&#x000a0; Routine BCG vaccination is not recommended in countries with a low prevalence of tuberculosis.&#x000a0; Routine BCG vaccination has never been recommended in the United States given the low prevalence of tuberculosis infection.&#x000a0; Routine BCG vaccination of children at age 13 and all neonates in high-risk groups was implemented between 1953 and 2005 in the United Kingdom.&#x000a0; Routine vaccination was later discontinued in 2005 due to a decreased incidence of tuberculosis infection.</p>
        <p>
<bold>Treatment of Bladder Cancer</bold>
</p>
        <p>A single dose of M. <italic toggle="yes">bovis</italic> bacillus Calmette-Gu&#x000e9;rin immunotherapy has a great therapeutic benefit in the treatment of non-invasive forms of bladder cancer. It is administered intravesically and proven benefits include the delay and prevent the progression of the malignancy.<xref ref-type="bibr" rid="article-18172.r24">[24]</xref><xref ref-type="bibr" rid="article-18172.r25">[25]</xref><xref ref-type="bibr" rid="article-18172.r26">[26]</xref></p>
      </sec>
      <sec id="article-18172.s4" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Immunocompromised patients</bold>
</p>
        <p>BCG is a live vaccine and should not be given to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunocompromised persons with congenital immunodeficiency, HIV infection, malignancy, or those taking immunosuppressive drugs such as tumor necrosis factor-alpha blockers and corticosteroids</p>
          </list-item>
          <list-item>
            <p>Adults with HIV infection living in areas of low TB prevalence</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18172.s5" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Injection site reaction is the most common complication. Injection site reaction includes granulomatous lesions, lymphadenopathy of regional lymph nodes, and nodules or ulcers at the vaccination site with or without draining sinus tracts or fistulae. <italic toggle="yes">Mycobacterium bovis&#x000a0;</italic>is positive when wound culture&#x000a0;is obtained.</p>
          </list-item>
          <list-item>
            <p>One of the adverse effects of BCG is suppurative lymphadenitis, children with primary immunodeficiencies have been shown to have a higher risk of widespread suppurative lymphadenitis and should be avoided.<xref ref-type="bibr" rid="article-18172.r27">[27]</xref><xref ref-type="bibr" rid="article-18172.r28">[28]</xref>&#x000a0;Other complications include:</p>
          </list-item>
          <list-item>
            <p>Osteitis</p>
          </list-item>
          <list-item>
            <p>Osteomyelitis</p>
          </list-item>
          <list-item>
            <p>Disseminated infection may occur in the setting of immunosuppression&#x000a0;including HIV infection.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18172.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>BCG vaccination after infancy has a substantial effect on tuberculin skin test (TST) reactivity.&#x000a0; BCG trial in the United States showed that individuals who received BCG after infancy had tuberculin skin test reactions &#x02265;10 mm up to 55 years post-immunization.<xref ref-type="bibr" rid="article-18172.r29">[29]</xref></p>
        <p>Prior BCG vaccination should not affect the interpretation of TST results in individuals vaccinated at birth more than ten years earlier given that most individuals who receive the BCG vaccine come from areas where there is a high incidence of TB. &#x000a0;Interferon-gamma release assays (IGRAs) should be used to interpret positive TSTs in persons with a history of BCG immunization since this test is not affected by BCG administration.&#x000a0; In individuals exposed to serial tuberculin testing, previous BCG vaccination may be increased, leading to a positive skin test in an individual with a prior negative skin test.&#x000a0;Greater than 50 percent of patients that received intravesical BCG for bladder cancer have been reported to result in conversion to a positive tuberculin skin test.&#x000a0;This exposure to intravesical BCG should not result in a positive IGRA result.<xref ref-type="bibr" rid="article-18172.r30">[30]</xref><xref ref-type="bibr" rid="article-18172.r31">[31]</xref></p>
        <p>The rationale for the development of a booster vaccine is due to decreasing immunity about 15-20 years after the initial immunization at infancy <xref ref-type="bibr" rid="article-18172.r32">[32]</xref>. However, studies done in Brazil and Malawi have shown that a booster dose of the BCG vaccine is not very effective against TB disease <xref ref-type="bibr" rid="article-18172.r33">[33]</xref><xref ref-type="bibr" rid="article-18172.r34">[34]</xref><xref ref-type="bibr" rid="article-18172.r35">[35]</xref>. BCG vaccine may offer protection against infections due to nontuberculous mycobacteria.<xref ref-type="bibr" rid="article-18172.r36">[36]</xref></p>
        <p>Studies have shown that the BCG vaccine decreases the risk of disease due to <italic toggle="yes">Mycobacterium leprae</italic> by 50 to 80 percent and this effect is increased with booster doses of BCG.<xref ref-type="bibr" rid="article-18172.r34">[34]</xref><xref ref-type="bibr" rid="article-18172.r37">[37]</xref>&#x000a0; Prior studies had shown that the vaccine is also 50 percent effective in preventing Buruli ulcer disease due to <italic toggle="yes">M. ulcerans, </italic>but a more recent retrospective study failed to show evidence that BCG protected against Buruli ulcer disease.<xref ref-type="bibr" rid="article-18172.r38">[38]</xref></p>
        <p>BCG vaccination also protects against childhood lymphadenitis due to <italic toggle="yes">M. avium</italic> complex <xref ref-type="bibr" rid="article-18172.r39">[39]</xref> has been an increase in childhood adenitis due to non-tuberculous mycobacteria since the cessation of childhood BCG immunization.<xref ref-type="bibr" rid="article-18172.r40">[40]</xref><xref ref-type="bibr" rid="article-18172.r41">[41]</xref></p>
        <p>Tuberculin skin test (TST)&#x000a0;reaction of 3 to 19 mm in size is expected in most individuals that received BCG immunization two to three months after vaccination.&#x000a0; In a study of 5952 individuals who had BCG vaccination and subsequently underwent tuberculin skin testing 10 to 25 years later, only 8 percent had positive skin test results.<xref ref-type="bibr" rid="article-18172.r31">[31]</xref></p>
      </sec>
      <sec id="article-18172.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>BCG vaccination policy is determined by the regional prevalence of tuberculosis infection. Routine neonatal vaccination is recommended by the WHO in countries with moderate to the severe incidence of tuberculosis.&#x000a0;Conversion of tuberculin skin test should not be used to determine the efficacy of the BCG vaccine among&#x000a0;recipients.<xref ref-type="bibr" rid="article-18172.r34">[34]</xref><xref ref-type="bibr" rid="article-18172.r35">[35]</xref><xref ref-type="bibr" rid="article-18172.r42">[42]</xref></p>
        <p>Routine BCG vaccination is not generally recommended in the United States due to a low incidence of tuberculosis infection and also due to interference of immunization with the PPD test. BCG vaccination is not recommended for health care workers in low-risk areas. Vaccination is also contraindicated in immunosuppressed patients.</p>
        <p>BCG vaccination may be considered in situations where a high percentage of patients are infected with TB strains that are resistant to isoniazid and rifampin.<xref ref-type="bibr" rid="article-18172.r42">[42]</xref>&#x000a0;Vaccination can also be found in&#x000a0;cases&#x000a0;where the implementation of general infection precautions has failed and when transmission of multi-drug resistant strain of<italic toggle="yes"> Mycobacterium tuberculosis</italic> is likely.<xref ref-type="bibr" rid="article-18172.r42">[42]</xref>&#x000a0;Nurses practitioners, physician&#x000a0;assistants, and physicians&#x000a0;that administer BCG should work together in an interprofessional team to assure the safe and effective administration, follow-up, and education of the patient. [Level 5]</p>
      </sec>
      <sec id="article-18172.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18172&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18172">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18172/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18172">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18172.s9">
        <title>References</title>
        <ref id="article-18172.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Reyn</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Vuola</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>New vaccines for the prevention of tuberculosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2002</year>
            <month>Aug</month>
            <day>15</day>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>465</fpage>
            <page-range>465-74</page-range>
            <pub-id pub-id-type="pmid">12145732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Biology of the mycobacterioses. Identification of the tuberculous-infected by skin tests.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>1968</year>
            <month>Sep</month>
            <day>05</day>
            <volume>154</volume>
            <issue>1</issue>
            <fpage>140</fpage>
            <page-range>140-8</page-range>
            <pub-id pub-id-type="pmid">5266317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fine</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Variation in protection by BCG: implications of and for heterologous immunity.</article-title>
            <source>Lancet</source>
            <year>1995</year>
            <month>Nov</month>
            <day>18</day>
            <volume>346</volume>
            <issue>8986</issue>
            <fpage>1339</fpage>
            <page-range>1339-45</page-range>
            <pub-id pub-id-type="pmid">7475776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrews</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Noubary</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Walensky</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Cerda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Losina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>784</fpage>
            <page-range>784-91</page-range>
            <pub-id pub-id-type="pmid">22267721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjartveit</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-11</page-range>
            <pub-id pub-id-type="pmid">12729334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HEIMBECK</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>BCG vaccination of nurses.</article-title>
            <source>Tubercle</source>
            <year>1948</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>84</fpage>
            <page-range>84-8</page-range>
            <pub-id pub-id-type="pmid">18909014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Beyers</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Spuy</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Borgdorff</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Enarson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van Helden</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2005</year>
            <month>Jun</month>
            <day>15</day>
            <volume>171</volume>
            <issue>12</issue>
            <fpage>1430</fpage>
            <page-range>1430-5</page-range>
            <pub-id pub-id-type="pmid">15831840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Reyn</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Reinfection with Mycobacterium tuberculosis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>173</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-4; author reply 134-5</page-range>
            <pub-id pub-id-type="pmid">16368796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lahey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mackenzie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arbeit</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Bakari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mtei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Matee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maro</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Pallangyo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>von Reyn</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>151</fpage>
            <page-range>151-8</page-range>
            <pub-id pub-id-type="pmid">22972862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zumla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raviglione</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hafner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>von Reyn</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Feb</month>
            <day>21</day>
            <volume>368</volume>
            <issue>8</issue>
            <fpage>745</fpage>
            <page-range>745-55</page-range>
            <pub-id pub-id-type="pmid">23425167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Stensballe</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Garly</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Beneficial non-targeted effects of BCG--ethical implications for the coming introduction of new TB vaccines.</article-title>
            <source>Tuberculosis (Edinb)</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>86</volume>
            <issue>6</issue>
            <fpage>397</fpage>
            <page-range>397-403</page-range>
            <pub-id pub-id-type="pmid">16901755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Garly</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Djana</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Sodemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Low birth weight infants and Calmette-Gu&#x000e9;rin bacillus vaccination at birth: community study from Guinea-Bissau.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>544</fpage>
            <page-range>544-50</page-range>
            <pub-id pub-id-type="pmid">15194836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristensen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa.</article-title>
            <source>BMJ</source>
            <year>2000</year>
            <month>Dec</month>
            <day>09</day>
            <volume>321</volume>
            <issue>7274</issue>
            <fpage>1435</fpage>
            <page-range>1435-8</page-range>
            <pub-id pub-id-type="pmid">11110734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleinnijenhuis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quintin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Preijers</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Joosten</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ifrim</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Loenhout</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stunnenberg</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Xavier</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van Crevel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Netea</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2012</year>
            <month>Oct</month>
            <day>23</day>
            <volume>109</volume>
            <issue>43</issue>
            <fpage>17537</fpage>
            <page-range>17537-42</page-range>
            <pub-id pub-id-type="pmid">22988082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeyanathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heriazon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Airway luminal T cells: a newcomer on the stage of TB vaccination strategies.</article-title>
            <source>Trends Immunol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>247</fpage>
            <page-range>247-52</page-range>
            <pub-id pub-id-type="pmid">20542470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horvath</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Shaler</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Jeyanathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zganiacz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells.</article-title>
            <source>Mucosal Immunol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>420</fpage>
            <page-range>420-31</page-range>
            <pub-id pub-id-type="pmid">22453678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lutwama</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kagina</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Wajja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waiswa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mansoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kirimunda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kiwanuka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Joloba</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Musoke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scriba</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Mayanja-Kizza</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hanekom</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.</article-title>
            <source>J Infect Dis</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>209</volume>
            <issue>6</issue>
            <fpage>887</fpage>
            <page-range>887-97</page-range>
            <pub-id pub-id-type="pmid">24179111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Barreto</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Pilger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sant'Anna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hijjar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ichihara</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Genser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>300</fpage>
            <page-range>300-6</page-range>
            <pub-id pub-id-type="pmid">22071248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <article-title>The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>1996</year>
            <month>Apr</month>
            <day>26</day>
            <volume>45</volume>
            <issue>RR-4</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">8602127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Acosta</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rusovich</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zellweger</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Centis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <collab>WHO EURO Childhood Task Force members</collab>
            </person-group>
            <article-title>Bacille Calmette-Gu&#x000e9;rin vaccination: the current situation in Europe.</article-title>
            <source>Eur Respir J</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-35</page-range>
            <pub-id pub-id-type="pmid">24381321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brewer</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Colditz</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Bacille Calmette-Gu&#x000e9;rin vaccination for the prevention of tuberculosis in health care workers.</article-title>
            <source>Clin Infect Dis</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <page-range>136-42</page-range>
            <pub-id pub-id-type="pmid">7727639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <article-title>Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease.</article-title>
            <source>Tuber Lung Dis</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-80</page-range>
            <pub-id pub-id-type="pmid">7919307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fine</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Stopping routine vaccination for tuberculosis in schools.</article-title>
            <source>BMJ</source>
            <year>2005</year>
            <month>Sep</month>
            <day>24</day>
            <volume>331</volume>
            <issue>7518</issue>
            <fpage>647</fpage>
            <page-range>647-8</page-range>
            <pub-id pub-id-type="pmid">16179677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyazaki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Onozawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takaoka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Bacillus Calmette-Gu&#x000e9;rin strain differences as the basis for immunotherapies against bladder cancer.</article-title>
            <source>Int J Urol</source>
            <year>2018</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>405</fpage>
            <page-range>405-413</page-range>
            <pub-id pub-id-type="pmid">29506322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hameed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sezian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thwaini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.</article-title>
            <source>Can J Urol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>3745</fpage>
            <page-range>3745-9</page-range>
            <pub-id pub-id-type="pmid">18163926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeGeorge</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Hodges</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Bladder Cancer: Diagnosis and Treatment.</article-title>
            <source>Am Fam Physician</source>
            <year>2017</year>
            <month>Oct</month>
            <day>15</day>
            <volume>96</volume>
            <issue>8</issue>
            <fpage>507</fpage>
            <page-range>507-514</page-range>
            <pub-id pub-id-type="pmid">29094888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolursaz</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lotfian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Velayati</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Bacillus Calmette-Gu&#x000e9;rin vaccine complications in Iranian children at a University Hospital.</article-title>
            <source>Allergol Immunopathol (Madr)</source>
            <year>2017</year>
            <season>Jul-Aug</season>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>356</fpage>
            <page-range>356-361</page-range>
            <pub-id pub-id-type="pmid">28161281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Hammadi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alsuwaidi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Alshamsi</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Ghatasheh</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Souid</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Disseminated Bacillus Calmette-Gu&#x000e9;rin (BCG) infections in infants with immunodeficiency.</article-title>
            <source>BMC Res Notes</source>
            <year>2017</year>
            <month>May</month>
            <day>05</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <pub-id pub-id-type="pmid">28476145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancuso</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Santosham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>The Long-term Effect of Bacille Calmette-Gu&#x000e9;rin Vaccination on Tuberculin&#x000a0;Skin Testing: A 55-Year Follow-Up Study.</article-title>
            <source>Chest</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>152</volume>
            <issue>2</issue>
            <fpage>282</fpage>
            <page-range>282-294</page-range>
            <pub-id pub-id-type="pmid">28087302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamm</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Bacillus Calmette-Guerin immunotherapy for bladder cancer.</article-title>
            <source>J Urol</source>
            <year>1985</year>
            <month>Jul</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-7</page-range>
            <pub-id pub-id-type="pmid">3892050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kavsak</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Garay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis.</article-title>
            <source>Clin Biochem</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>913</fpage>
            <page-range>913-5</page-range>
            <pub-id pub-id-type="pmid">17512514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Reyn</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Correcting the record on BCG before we license new vaccines against tuberculosis.</article-title>
            <source>J R Soc Med</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>110</volume>
            <issue>11</issue>
            <fpage>428</fpage>
            <page-range>428-433</page-range>
            <pub-id pub-id-type="pmid">28949270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Floyd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bliss</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warndorff</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Crampin</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ngwira</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sichali</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nazareth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackwell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Branson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaguluka</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jarman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Dockrell</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Apr</month>
            <day>20</day>
            <volume>359</volume>
            <issue>9315</issue>
            <fpage>1393</fpage>
            <page-range>1393-401</page-range>
            <pub-id pub-id-type="pmid">11978337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <article-title>Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.</article-title>
            <source>Lancet</source>
            <year>1996</year>
            <month>Jul</month>
            <day>06</day>
            <volume>348</volume>
            <issue>9019</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">8691924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodrigues</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Genser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ichihara</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>de Brito</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hijjar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dourado</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sant'Anna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bierrenbach</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Barreto</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial.</article-title>
            <source>Lancet</source>
            <year>2005</year>
            <month>Oct</month>
            <day>08</day>
            <volume>366</volume>
            <issue>9493</issue>
            <fpage>1290</fpage>
            <page-range>1290-5</page-range>
            <pub-id pub-id-type="pmid">16214599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimmermann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis.</article-title>
            <source>J Infect Dis</source>
            <year>2018</year>
            <month>Jul</month>
            <day>24</day>
            <volume>218</volume>
            <issue>5</issue>
            <fpage>679</fpage>
            <page-range>679-687</page-range>
            <pub-id pub-id-type="pmid">29635431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merle</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control.</article-title>
            <source>Expert Rev Vaccines</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-22</page-range>
            <pub-id pub-id-type="pmid">20109030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Phanzu</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Beissner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badziklou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luzolo</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Sarfo</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Halatoko</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Amoako</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Frimpong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kabiru</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Piten</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bidjada</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Awoussi</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kobara</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nitschke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiedemann</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Kere</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Adjei</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>L&#x000f6;scher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bretzel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Herbinger</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>e3457</fpage>
            <pub-id pub-id-type="pmid">25569674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katila</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Brander</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Backman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood.</article-title>
            <source>Tubercle</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-6</page-range>
            <pub-id pub-id-type="pmid">3138802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romanus</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hallander</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>W&#x000e5;hl&#x000e9;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olinder-Nielsen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Magnusson</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Juhlin</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage.</article-title>
            <source>Tuber Lung Dis</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>300</fpage>
            <page-range>300-10</page-range>
            <pub-id pub-id-type="pmid">7579311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kontturi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soini</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ollgren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Salo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Gu&#x000e9;rin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016.</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <day>28</day>
            <volume>67</volume>
            <issue>8</issue>
            <fpage>1256</fpage>
            <page-range>1256-1261</page-range>
            <pub-id pub-id-type="pmid">29584893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18172.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Chan-Yeung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>717</fpage>
            <page-range>717-23</page-range>
            <pub-id pub-id-type="pmid">11495262</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
